Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Editorial comment on: "The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced non-small cell lung cancer receiving palliative chemotherapy". by Vincent et al.

× No keyword cloud information.

17 in total

1. Breast cancer trial with erythropoietin terminated unexpectedly.

Authors: Brian Leyland-Jones
Journal: Lancet Oncol Date: 2003-08 Impact factor: 41.316

Review 2. The blue cross blue shield assessment technology review: summary of findings.

Authors: Charles L Bennett
Journal: Best Pract Res Clin Haematol Date: 2005 Impact factor: 3.020

Review 3. Fatigue: a main component of anemia symptomatology.

Authors: A Sobrero; F Puglisi; A Guglielmi; O Belvedere; G Aprile; M Ramello; F Grossi
Journal: Semin Oncol Date: 2001-04 Impact factor: 4.929

4. The use of erythropoietin in patients undergoing radical prostatectomy: effects on hematocrit, transfusion rates and quality of life.

Authors: Kris E Gaston; Erik Kouba; Dominic T Moore; Raj S Pruthi
Journal: Urol Int Date: 2006 Impact factor: 2.089

5. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.

Authors: G A Curt; W Breitbart; D Cella; J E Groopman; S J Horning; L M Itri; D H Johnson; C Miaskowski; S L Scherr; R K Portenoy; N J Vogelzang
Journal: Oncologist Date: 2000

Review 6. Cancer patient survival and erythropoietin.

Authors: John A Glaspy
Journal: J Natl Compr Canc Netw Date: 2005-11 Impact factor: 11.908

Review 7. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes.

Authors: D Cella; D Dobrez; J Glaspy
Journal: Ann Oncol Date: 2003-04 Impact factor: 32.976

8. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

Authors: Thomas E Witzig; Peter T Silberstein; Charles L Loprinzi; Jeff A Sloan; Paul J Novotny; James A Mailliard; Kendrith M Rowland; Steven R Alberts; James E Krook; Ralph Levitt; Roscoe F Morton
Journal: J Clin Oncol Date: 2004-09-27 Impact factor: 44.544

9. [Standards, options and recommendations for the use of recombinant erythropoietin (epoietin alpha and beta darbepoietin-alpha, EPO) in the management of anaemia in oncology for patient undergoing radiotherapy-update 2003].

Authors: Christian Marchal; Dominique Spaeth; Nicole Casadevall; Mikaël Daouphars; Perrine Marec-Berard; Nicolas Fabre; Margaret Haugh
Journal: Cancer Radiother Date: 2004-06 Impact factor: 1.018

10. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

Authors: J Douglas Rizzo; Alan E Lichtin; Steven H Woolf; Jerome Seidenfeld; Charles L Bennett; David Cella; Benjamin Djulbegovic; Matthew J Goode; Ann A Jakubowski; Stephanie J Lee; Carole B Miller; Mark U Rarick; David H Regan; George P Browman; Michael S Gordon
Journal: J Clin Oncol Date: 2002-10-01 Impact factor: 44.544